Your browser doesn't support javascript.
loading
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
Gurwith, Marc; Condit, Richard C; Excler, Jean-Louis; Robertson, James S; Kim, Denny; Fast, Patricia E; Drew, Stephen; Wood, David; Klug, Bettina; Whelan, Mike; Mallett Moore, Tamala; Khuri-Bulos, Najwa; Smith, Emily R; Chen, Robert T; Kochhar, Sonali.
Afiliação
  • Gurwith M; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.
  • Condit RC; Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.
  • Excler JL; International Vaccine Institute, Seoul, Republic of Korea.
  • Robertson JS; Independent Adviser, United Kingdom.
  • Kim D; Janssen Pharmaceuticals, Titusville, NJ, USA.
  • Fast PE; International AIDS Vaccine Initiative, New York, NY, USA; Stanford School of Medicine, Paolo Alto, CA, USA.
  • Drew S; Independent Adviser, USA.
  • Wood D; Independent Adviser, United Kingdom.
  • Klug B; Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
  • Whelan M; Project Leader, CEPI, UK.
  • Mallett Moore T; Sanofi Pasteur, Swiftwater, PA, USA.
  • Khuri-Bulos N; University of Jordan, Amman, Jordan.
  • Smith ER; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA. Electronic address: bc-coordinator@taskforce.org.
  • Chen RT; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.
  • Kochhar S; Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA, USA.
Vaccine ; 38(49): 7702-7707, 2020 11 17.
Article em En | MEDLINE | ID: mdl-33070999
ABSTRACT
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Atenuadas / Vacinas Virais / Avaliação Pré-Clínica de Medicamentos Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Atenuadas / Vacinas Virais / Avaliação Pré-Clínica de Medicamentos Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article